OBJECTIVES: A budget impact model was developed in order to estimate the economic impact of increased pantoprazole intravenous prescription in the management of  Peptic Ulcer (PU) in Spain.  METHODS: The analytic model is based on data from disease prevalence, population growth, drug consumption, ex-factory prices and market shares forecasts for the Spanish market. It takes the perspective of the Spanish National Health Care System and time horizon considered is 5 years (annual discount rate at 5%). Drugs considered in the study were intravenous proton-pump inhibitors (PPIs): omeprazole, esomeprazole and pantoprazole. The model estimates the annual cost to treat patients with PU before and after of increased pantoprazol IV prescription. Annual costs includes pharmacologic treatment, laboratory and diagnostic tests, specialist consultation, hospitalization and other resources like transfusions, endoscopic treatments and surgery interventions. Health care resource consumption and unit costs have been obtained from a retrospective observational study that evaluated the re-bleeding prevalence by PU in patients treated with intravenous PPIs. All costs are referred to year 2007. RESULTS: Target population with peptic ulcer in Spain would be around 362,193 in year 2007, arriving at 378,048 in 2012 due to increase in Spanish population. Of these population it has been estimated that 5092 patients in year 2007 would be treated with intravenous PIPs (5315 patients in year 2012). Direct medical costs for the next 5 years for PU was estimated at €78.5 million before the increased pantoprazole prescription and at €77 million after its increase. Mean cost per patient was estimated at 2,513€ before the increase the pantoprazole participation and at 2464 after its increase. CONCLUSIONS: This budget impact model estimates that an increased intravenous pantoprazole prescription for the treatment of PU in Spain is going to represent a net savings of €1.5 million in the Spanish Health Care System in the next five years.